Gerresheimer Shares Rally as Goldman Stake Eases Takeover Jitters, but Audit Clock Ticks
Published on 06/23/2026 at 17:12 | Redaktion boerse-global.de
Goldman Sachs has thrown a lifeline to Gerresheimer’s rattled shareholders – but the packaging specialist still faces a high-stakes race against the clock to deliver audited accounts by the end of June. The US investment bank disclosed it now holds just under 20% of the voting rights, a stake that initially stoked fears of a hostile bid or activist intervention. However, Goldman quickly clarified the position is purely a routine part of its client servicing business, with no strategic designs or boardroom ambitions. The move sent the stock up 6% in the past seven days to close at €25.96, and by Tuesday it had climbed further to €27.88, pushing comfortably above its 200-day moving average for the first time in weeks.
Yet the sense of relief is tempered by the weight of regulatory scrutiny. The Federal Financial Supervisory Authority (BaFin) is poring over Gerresheimer’s books, focusing on a potential €196 million impairment in the Advanced Technologies division, possible errors in lease liabilities of €65 million, and irregularities in capitalised development costs. The company must submit its audited 2025 annual financial statements before the end of this month or risk a severe market backlash. Analysts warn that a clean delivery could bring an upside target of €46 back into play, while any further delay might trigger a slide to €13.
Management is not waiting idly for auditors to finish. The sale of US subsidiary Centor is under way, with a double-digit number of suitors already in the data room. That proceeds are badly needed: the group’s lenders have already stepped in to buy time, agreeing to suspend key debt covenants on a €870 million Schuldschein loan until the end of September 2026. That concession buys breathing room but does not solve the underlying need to clean up the balance sheet.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Chartwise, the stock is showing tentative signs of life. The 14-day relative strength index sits at 53.4, a neutral reading that suggests neither overwhelming buying nor selling pressure. Still, the medium-term picture remains bleak. The shares have lost 43% over the past twelve months, are down 6% year-to-date, and trade nearly 50% below their 52-week high of €50.25. A 30-day annualised volatility of nearly 44% underscores how far the company is from the stability investors crave.
For now, the Goldman stake has taken the edge off speculation about aggressive structural change. But with the audit deadline looming and a sale process that is still in its early stages, Gerresheimer’s path to recovery runs squarely through the delivery of clean numbers – and that outcome is far from certain.
Ad
Gerresheimer Stock: New Analysis - 23 June
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
